## Immune Response and Pathophysiology of SARS-CoV-2 ### Innate Immune Recognition **Key Point:** SARS-CoV-2 RNA is recognized by pattern recognition receptors (PRRs), particularly Toll-like receptors (TLRs) 3, 7, and 8, which trigger interferon and inflammatory responses. **High-Yield:** TLR3 recognizes double-stranded RNA in endosomes; TLR7 and TLR8 recognize single-stranded RNA in endosomal compartments. ### Viral Evasion Mechanisms **Key Point:** Non-structural protein 1 (nsp1) is a key immune evasion factor that inhibits interferon-beta (IFN-β) production and suppresses the antiviral response. **Clinical Pearl:** Other viral proteins (nsp3, nsp5, nsp15) also antagonize interferon signaling, contributing to viral persistence in severe disease. ### Adaptive Immune Response and Antibody Kinetics **High-Yield:** Spike-specific IgM appears around day 3–5, followed by IgG around day 7–10 after symptom onset. **Warning:** Early antibodies do NOT provide sterilizing immunity. Sterilizing immunity requires: - High-titer neutralizing antibodies (nAbs) - Robust T-cell responses (CD4+ and CD8+) - Time for antibody maturation and affinity refinement **Key Point:** Antibodies alone, especially early IgM, are insufficient to clear infection. Cellular immunity (CD8+ T cells) is essential for viral clearance and protection against reinfection. ### Severe COVID-19 Immunopathology **Key Point:** Severe disease is characterized by a **cytokine storm** with elevated: - IL-6 (interleukin-6) - TNF-α (tumor necrosis factor-alpha) - IL-8 (interleukin-8) - IL-1β, IL-17 **Mnemonic:** **STIFF** = **S**pike-driven **T**h1/**T**h17, **I**nflammatory **F**actors, **F**ibrin deposition — hallmarks of severe COVID-19. **Clinical Pearl:** This hyperinflammatory state, rather than viral burden alone, drives acute respiratory distress syndrome (ARDS), thrombosis, and multi-organ failure in severe COVID-19. ### Timeline of Immune Response ```mermaid flowchart TD A[Day 0-2: Viral entry and replication]:::outcome --> B[TLR recognition, IFN production]:::action B --> C[Day 3-5: IgM antibodies appear]:::outcome C --> D[Day 5-8: CD8+ T-cell response peaks]:::action D --> E{Adequate immune control?}:::decision E -->|Yes| F[Viral clearance, recovery]:::outcome E -->|No| G[Persistent replication, cytokine storm]:::urgent G --> H[ARDS, multi-organ failure]:::urgent ``` **Warning:** Early antibodies (IgM/early IgG) do NOT equal protection. Neutralizing antibody titer and T-cell immunity are the true correlates of protection.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.